They can’t blame Bush for this one: A Singapore company that made a big splash when it announced it would soon be offering ES cell therapies to human patients—has backed off. From the story in Science July 2007: Vol. 317. no. 5836, p. 305 (no link):
In a sign that hopes for quick medical benefits from stem cells are fading, ES Cell International (ESI)—a company established with fanfare in Singapore 7 years ago—is halting work on human embryonic stem (hES) cell therapies. Investors lost interest because “the likelihood of having products in the clinic in the short term was vanishingly small,” says Alan Colman, a stem cell pioneer who until last month was ESI’s chief executive. ESI’s setback may dampen investors’ enthusiasm for stem cell therapies, says Robert Lanza, vice president for R&D at Advanced Cell Technology in Worcester, Massachusetts: “What the field badly needs is one or two success stories.”
…The company was attempting to turn hES cells into insulin-producing cells to treat diabetes and cardiac muscle cells to counter congestive heart failure. Both conditions represent major markets with unmet clinical needs, but making well-functioning insulin-producing cells “proved really difficult,” Colman says. Both envisioned therapies would need at least a billion cells for each human dose. Producing such numbers at the required purity “becomes very expensive,” Colman says, and meeting these challenges would have taken longer than investors have patience for.
There is much whistling past the graveyard in the story, as well. For example, a spokesman for Geron Corporation claims that the company expects to begin human trials for spinal cord injury in 2008. The only thing is, it said the same thing for the years 2005, 2006, and 2007. Time will tell.
Dear Reader,
Can I be direct with you?
War abroad. Socialists on the rise. AI upending human life. Endless uproar online. The modern attention economy doesn’t want readers — it wants users enslaved to the tyranny of the present.
First Things is the antidote: literary excellence, timeless truths, and a fixed point of reference in a culture that has lost its bearings.
But we can’t do it without readers like you.
Our goal: Raise $150,000 by November 1 to sustain First Things in the year ahead.
Your gift anchors readers in the permanent things.
Make your Fall Campaign gift now using the button below.
If you have any questions or would like more information, please contact Giovanni Del Piero, Director of the Editor’s Circle, at gdelpiero@firstthings.com or 212-627-1985.
YOU MIGHT ALSO LIKE
The Church in the Age of Therapy
In 1966, Philip Rieff wrote in The Triumph of the Therapeutic that “Religious man was born to…
Canada’s Deadliest Blind Spot
On September 20, the Daily Mail ran a story with the provocative headline, “Our 83-year-old Christian grandmother…
The Faithful Joy of Dolly Parton and Fulton Sheen
Dolly Parton and Fulton Sheen seem to have had little in common. She favored rhinestones; he wore…
